Viyash Scientific Limited (SEQUENT) - Total Assets
Based on the latest financial reports, Viyash Scientific Limited (SEQUENT) holds total assets worth Rs17.26 Billion INR (≈ $186.67 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Viyash Scientific Limited (SEQUENT) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Viyash Scientific Limited - Total Assets Trend (2006–2025)
This chart illustrates how Viyash Scientific Limited's total assets have evolved over time, based on quarterly financial data. See Viyash Scientific Limited (SEQUENT) shareholders funds for net asset value and shareholders' equity analysis.
Viyash Scientific Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Viyash Scientific Limited's total assets of Rs17.26 Billion consist of 54.5% current assets and 45.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 4.3% |
| Accounts Receivable | Rs3.63 Billion | 22.7% |
| Inventory | Rs3.85 Billion | 24.1% |
| Property, Plant & Equipment | Rs2.99 Billion | 18.7% |
| Intangible Assets | Rs534.50 Million | 3.3% |
| Goodwill | Rs2.49 Billion | 15.5% |
Asset Composition Trend (2006–2025)
This chart illustrates how Viyash Scientific Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Viyash Scientific Limited stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viyash Scientific Limited's current assets represent 54.5% of total assets in 2025, an increase from 52.5% in 2006.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2025, up from 3.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 24.1% of total assets.
Viyash Scientific Limited Competitors by Total Assets
Key competitors of Viyash Scientific Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.03 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Humanwell Healthcare Group Co Ltd
SHG:600079
|
China | CN¥37.56 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Viyash Scientific Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 1.70 | 1.45 |
| Quick Ratio | 1.08 | 0.96 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs4.57 Billion | Rs3.40 Billion | Rs2.79 Billion |
Viyash Scientific Limited - Advanced Valuation Insights
This section examines the relationship between Viyash Scientific Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.16 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | Rs16.02 Billion |
| Market Capitalization | $529.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Viyash Scientific Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Viyash Scientific Limited's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Viyash Scientific Limited (2006–2025)
The table below shows the annual total assets of Viyash Scientific Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs16.02 Billion ≈ $173.24 Million |
+4.00% |
| 2024-03-31 | Rs15.40 Billion ≈ $166.59 Million |
+0.74% |
| 2023-03-31 | Rs15.29 Billion ≈ $165.37 Million |
+5.39% |
| 2022-03-31 | Rs14.51 Billion ≈ $156.92 Million |
+4.19% |
| 2021-03-31 | Rs13.93 Billion ≈ $150.60 Million |
-4.79% |
| 2020-03-31 | Rs14.63 Billion ≈ $158.18 Million |
+5.39% |
| 2019-03-31 | Rs13.88 Billion ≈ $150.09 Million |
+3.36% |
| 2018-03-31 | Rs13.43 Billion ≈ $145.21 Million |
-29.50% |
| 2017-03-31 | Rs19.05 Billion ≈ $205.98 Million |
+24.64% |
| 2016-03-31 | Rs15.28 Billion ≈ $165.26 Million |
+68.35% |
| 2015-03-31 | Rs9.08 Billion ≈ $98.16 Million |
+45.76% |
| 2014-03-31 | Rs6.23 Billion ≈ $67.34 Million |
+6.22% |
| 2013-03-31 | Rs5.86 Billion ≈ $63.40 Million |
+7.11% |
| 2012-03-31 | Rs5.47 Billion ≈ $59.19 Million |
+21.68% |
| 2011-03-31 | Rs4.50 Billion ≈ $48.65 Million |
+17.76% |
| 2010-03-31 | Rs3.82 Billion ≈ $41.31 Million |
+49.49% |
| 2009-03-31 | Rs2.56 Billion ≈ $27.63 Million |
+154.66% |
| 2008-03-31 | Rs1.00 Billion ≈ $10.85 Million |
+101.37% |
| 2007-03-31 | Rs498.25 Million ≈ $5.39 Million |
+81.44% |
| 2006-03-31 | Rs274.60 Million ≈ $2.97 Million |
-- |
About Viyash Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was former… Read more